Sprayable peptide-modified silver nanoparticles as a barrier against bacterial colonization.
Sprayable formulations of AgNPs were prepared by exchanging citrate capping agents with LL37-SH peptides. The AgNP@LL37 material was then combined with type I collagen to form a stable film once sprayed. The AgNP@LL37 spray prevented Pseudomonas aeruginosa (P. aeruginosa) proliferation and eradicated a P. aeruginosa biofilm, while being non-toxic for human skin fibroblasts embedded within 3D artificial skin constructs. Finally, no silver infiltration was observed after spraying on a full-thickness skin wound in a mouse model.
Division of Cardiac Surgery Research, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario K1Y 4W7, Canada. esuuronen@ottawaheart.ca ealarcon@ottawaheart.ca.
Sarah
S
McLaughlin
Division of Cardiac Surgery Research, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario K1Y 4W7, Canada. esuuronen@ottawaheart.ca ealarcon@ottawaheart.ca.
Manuel
M
Ahumada
Wellman Centre for Photomedicine, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Walfre
W
Franco
Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Thien-Fah
TF
Mah
Division of Cardiac Surgery Research, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario K1Y 4W7, Canada. esuuronen@ottawaheart.ca ealarcon@ottawaheart.ca.
Richard
R
Seymour
Division of Cardiac Surgery Research, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario K1Y 4W7, Canada. esuuronen@ottawaheart.ca ealarcon@ottawaheart.ca.
Erik J
EJ
Suuronen
Division of Cardiac Surgery Research, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario K1Y 4W7, Canada. esuuronen@ottawaheart.ca ealarcon@ottawaheart.ca and Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Emilio I
EI
Alarcon
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D005347:Fibroblasts / Q000382:microbiology; D006801:Humans; D053768:Metal Nanoparticles; D010455:Peptides; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012834:Silver / Q000494:pharmacology*; D014947:Wounds and Injuries / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D010455:Peptides; D012834:Silver